DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
301	黄斑ジストロフィー	1

告示番号

疾患名（ページ内リンク）

臨床試験数

301

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02230228 (ClinicalTrials.gov)	April 2014	27/8/2014	Phase 1 Safety Study of ALK-001 in Healthy Volunteers	A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers	Stargardt Disease;Age-related Macular Degeneration;Other Retinal Dystrophies	Drug: ALK-001 (No generic name)	Alkeus Pharmaceuticals, Inc.	NULL	Completed	21 Years	70 Years	Both	40	Phase 1	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

April 2014

27/8/2014

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers

Stargardt Disease;Age-related Macular Degeneration;Other Retinal Dystrophies

Drug: ALK-001 (No generic name)

Alkeus Pharmaceuticals, Inc.

NULL

Completed

21 Years

70 Years

Both

Phase 1

NULL